HYPERION sotatercept study has positive results, stops early

PHA Canada
Feb 10, 2025
1 min read

The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial hypertension reduced the risk of disease progression. The trial was stopped early so all patients in the trial, including those in the placebo arm, can benefit from sotatercept. Patients in the trial will be able to receive sotatercept through the ongoing SOTERIA extension study.

Study results have not yet been published.

Read the press release here

Recent Posts

Sotatercept lowers blood volume but increases exercise ability

In a study of a relatively low-risk population of pulmonary hypertension patients, researchers began to untangle sotatercept's complex effects on exercise. Sotatercept lowered blood volume to normal l

AI May Help Predict PAH Patients' Risk of Worsening

Researchers looked at the medical records of 455 people with pulmonary arterial hypertension (PAH) to find factors associated with getting worse. Using a machine-learning computer model, they found 11

Sotatercept and cardiopulmonary comorbidities

This study from one clinic examined how well sotatercept worked in real-world patients with pulmonary arterial hypertension (PAH) who also had other heart or lung conditions, such as coronary artery d